Premium
Aripiprazole augmentation of antidepressant improves chance of remission in VA population
Publication year - 2017
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30270
Subject(s) - aripiprazole , bupropion , medicine , antidepressant , adverse effect , depression (economics) , veterans affairs , psychiatry , anesthesia , schizophrenia (object oriented programming) , smoking cessation , anxiety , pathology , economics , macroeconomics
A study conducted in the Department of Veterans Affairs (VA) health system has found that for patients with depression unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a modest increased likelihood of remission when compared with antidepressant switching or augmentation with bupropion. The aripiprazole group was more prone to adverse effects such as weight gain, but other adverse effects were more prominent in the other two patient groups. Study results were published July 11 in JAMA .